Johnson & Johnson vs. Viking Therapeutics, Inc
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 6 compared factors.
Size & Scale
| JNJ | VKTX | |
|---|---|---|
| Market Cap | $650.65 billion | $3.38 billion |
| Revenue (TTM) | $97.93 billion | — |
| Net Income (TTM) | $21.04 billion | $-534,796,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | VKTX | |
|---|---|---|
| P/E Ratio | 31.26 | — |
| Price / Book | 7.66 | 8.28 |
| Price / Sales | 6.64 | — |
JNJ leads on 1 of 1 valuation factors.
Profitability
| JNJ | VKTX | |
|---|---|---|
| Net Margin | 21.48% | — |
| Return on Equity | 24.76% | -130.98% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| JNJ | VKTX | |
|---|---|---|
| Dividend Yield | 1.99% | — |
| Payout Ratio | 62.18 | — |
JNJ and VKTX split the dividend factors evenly.
Risk & Sentiment
| JNJ | VKTX | |
|---|---|---|
| Short Interest | 0.67% | 1.14% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, VKTX overview, VKTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.